Nadia Mensali
- Researcher; PhD, Msc
- +47 22 78 23 19
ERA PerMed (IPerGlio)
Education
2015/-: Postdoc in Cellular Therapy (CAR, TCR, vaccines and NK-TCR)
2008/2015 : Ph.D. in Tumour Immunology, Faculty of Medicine, University of Oslo, Norway
2003/2004: Master in Clinic and Experimental Citometry, University of Urbino, Italy
1995/2001: Laurea in Biology, section Physiopathology, University of Urbino, Italy
Research interests/projects
Adoptive T-cell therapy
- pre-clinical validation of TCRs for therapeutic use
- pre-clinical validation of universal killer T cells
- development of novel technologies to improve cell-based therapy
Antigen presentation
- validation of novel methods to improve antigen presentation in the context of vaccination
- invariant chain as a tool for patient vaccination
Work experiences
2016/present: Postdoc Fellow, Dept of Cellular Therapy, OUS Radiumhospitalet, Oslo, Norway
2014/2015: Researcher, Dept of Biosciences, University of Oslo, Oslo, Norway
2008/2014: PhD Student, Department of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway
2007/2008: Laboratory Research Analyst II, Duke Center for AIDS Research (CFAR) at the Department of Surgery, Duke University Medical Center, Durham, NC, US
2005/2007: Laboratory Research Analyst I, Duke Center for AIDS Research (CFAR) at the Department of Surgery, Duke University Medical Center, Durham, NC, US
2002/2004: Biologist, Laboratory of Onco-Hematology, Flow Cytometry Laboratory, at the Center for Bone Marrow Transplant, “San Salvatore” Hospital, Pesaro, Italy.
1999/2001: Internship, Center of Cytometry and Cytomorphology, University of Urbino, Italy
Publications 2024
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
Mol Ther, 32 (6), 2021-2029
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964
Publications 2023
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
Nat Commun, 14 (1), 3375
DOI 10.1038/s41467-023-39097-x, PubMed 37291203
Publications 2022
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827
Emerging Biomarkers for Immunotherapy in Glioblastoma
Cancers (Basel), 14 (8)
DOI 10.3390/cancers14081940, PubMed 35454848
Publications 2021
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms
FASEB J, 35 (9), e21750
DOI 10.1096/fj.202100025R, PubMed 34424568
Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton
J Cell Sci, 134 (18)
DOI 10.1242/jcs.259221, PubMed 34494097
Publications 2020
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 69 (1), 159-161
DOI 10.1007/s00262-019-02409-6, PubMed 31776597
Posttransplantation Lymphoproliferative Disease Treated by Retransplantation
Case Reports Immunol, 2020, 9403123
DOI 10.1155/2020/9403123, PubMed 32158568
Publications 2019
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732
Publications 2017
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Cancer Immunol Immunother, 67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956
Publications 2016
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957
Publications 2015
Unpredicted phenotypes of two mutants of the TcR DMF5
J Immunol Methods, 425, 37-44
DOI 10.1016/j.jim.2015.06.006, PubMed 26079729
Publications 2011
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells
Int J Cancer, 130 (8), 1821-32
DOI 10.1002/ijc.26209, PubMed 21630262
Publications 2008
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design
J Virol, 82 (15), 7700-10
DOI 10.1128/JVI.00605-08, PubMed 18508902